D910LC00001

Research code: D910LC00001
Research name: Multicentre double-blind, placebo-controlled phase III research evaluating the efficacy of adjuvant therapy with durvalumab in combination with platinum derivative-based chemotherapy for the treatment of patients with stage II and III non-small cell lung cancer after complete resection (MeRmaiD-1).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD